<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">European Prevention of Alzheimer's Dementia (EPAD)</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>EPAD Consortium Logo</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Pan-European (coordinated from Edinburgh, UK)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research Consortium</td>
</tr>
<tr>
<td class="label">Launched</td>
<td>2015</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Completed (2022)</td>
</tr>
<tr>
<td class="label">Coordinator</td>
<td>University of Edinburgh</td>
</tr>
<tr>
<td class="label">Funding</td>
<td>€64 million (EU Horizon 2020)</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.ep-ad.org/" target="_blank">ep-ad.org</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers) Prevention, Clinical Trials, Biomarkers, Early Detection</td>
</tr>
</table>
<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">European Prevention of Alzheimer's Dementia (EPAD)</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>EPAD Consortium Logo</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Pan-European (coordinated from Edinburgh, UK)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research Consortium</td>
</tr>
<tr>
<td class="label">Launched</td>
<td>2015</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Completed (2022)</td>
</tr>
<tr>
<td class="label">Coordinator</td>
<td>University of Edinburgh</td>
</tr>
<tr>
<td class="label">Funding</td>
<td>€64 million (EU Horizon 2020)</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.ep-ad.org/" target="_blank">ep-ad.org</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers) Prevention, Clinical Trials, Biomarkers, Early Detection</td>
</tr>
</table>
The European Prevention of Alzheimer's Dementia (EPAD) was a ambitious pan-European research consortium dedicated to preventing Alzheimer's disease dementia through innovative clinical trial designs and comprehensive biomarker research. Launched in 2015 with €64 million in funding from the European Union's Horizon 2020 research program, EPAD represented one of the largest coordinated efforts to understand and prevent Alzheimer's disease in Europe [@european].
EPAD was designed to address a critical bottleneck in Alzheimer's disease research: the difficulty of conducting clinical trials for prevention therapies. By creating a unified registry of research participants and standardizing biomarker assessment across Europe, EPAD aimed to accelerate the development of effective treatments that could be administered years before symptoms appear [@ritchie2020].
The consortium was coordinated by the University of Edinburgh and brought together over 40 academic and industry partners across more than 20 European countries. EPAD built upon the foundation established by the Dominantly Inherited Alzheimer Network (DIAN) in the United States, extending the prevention trial model to sporadic Alzheimer's disease, which accounts for over 95% of cases [@dominantly].
EPAD's primary mission was to develop and validate markers of Alzheimer's disease progression to enable effective prevention trials in individuals at risk of developing dementia. The consortium pursued several key objectives:
The cornerstone of EPAD was its Longitudinal Cohort Study, which enrolled approximately 2,000 participants across over 100 sites in Europe. Participants were selected to represent different stages of Alzheimer's disease pathology, from cognitively normal individuals to those with mild cognitive impairment [@solomon2018].
The cohort was designed with the following characteristics:
The EPAD Registry was designed as a pan-European database of individuals interested in participating in Alzheimer's prevention research. Unlike traditional patient registries, EPAD proactively recruited cognitively healthy individuals at various levels of Alzheimer's disease risk, creating a pipeline for clinical trial enrollment [@epad].
The registry utilized a staged risk enrichment approach:
EPAD established standardized protocols for:
The POINER (Proof of Concept Immunotherapy in Alzheimer's Disease) study was EPAD's first clinical trial, evaluating the effects of gosuranemab, an anti-tau monoclonal antibody, in individuals with preclinical Alzheimer's disease. This study demonstrated the feasibility of recruiting and retaining participants in prevention trials using the EPAD infrastructure [@poiner].
The AMARANTH study evaluated elenbecestat, a BACE inhibitor developed by Eisai, in individuals with preclinical Alzheimer's disease. Although the trial was discontinued due to safety concerns unrelated to efficacy, it provided valuable data on BACE inhibition in early disease stages [@amaranth].
EPAD supported multiple secondary prevention trials, including studies targeting:
EPAD made significant contributions to Alzheimer's disease biomarker research:
The consortium validated the use of CSF biomarkers for identifying individuals with preclinical Alzheimer's disease, confirming that:
EPAD researchers explored novel fluid biomarkers including:
The consortium also investigated digital cognitive assessments and wearable device data as potential biomarkers for early cognitive decline [@koychev2021].
EPAD brought together leading European research institutions, including:
EPAD has made lasting contributions to Alzheimer's disease research:
EPAD produced over 100 peer-reviewed publications, covering topics from biomarker validation to clinical trial methodology. Key publications include:
Following the completion of EPAD in 2022, the consortium's infrastructure transitioned to the REAlity of Life (REAL) initiative, which continues to follow the EPAD cohort longitudinally and serves as a platform for new prevention trials [@real].
EPAD was closely related to the US Dominantly Inherited Alzheimer Network (DIAN), which studies individuals with genetic forms of Alzheimer's disease. While DIAN focuses on autosomal dominant AD (caused by mutations in [APP](/genes/APP), [PSEN1](/genes/PSEN1), or [PSEN2](/genes/PSEN2)), EPAD focused on sporadic AD, which is far more common [@dominantly].
The US Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) study was another key prevention trial that paralleled EPAD's efforts. EPAD and A4 shared methodological approaches and collaborated on biomarker standardization [@sperling2014].
EPAD was a founding member of the Global Alzheimer's Association Interactive Network (GAAIN), which aims to share data across international Alzheimer's research consortia [@global].
The learnings from EPAD continue to inform current Alzheimer's prevention initiatives: